Log in
OTCMKTS:EKTAY

Elekta AB (publ) Stock Forecast, Price & News

$13.28
+0.80 (+6.41 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$13.24
Now: $13.28▼
$13.40
50-Day Range
$11.50
MA: $12.55▼
$13.26
52-Week Range
$6.25
Now: $13.28▼
$13.86
Volume4,463 shs
Average Volume9,269 shs
Market Capitalization$5.07 billion
P/E Ratio37.74
Dividend Yield1.12%
Beta0.78
Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Read More
Elekta AB (publ) logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.71 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EKTAY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.elekta.com
Phone46-8-587-254-00
Employees3,800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio37.74
Forward P/E Ratio30.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.44 billion
Price / Sales3.53
Cash Flow$0.63 per share
Price / Cash Flow21.19
Book Value$2.26 per share
Price / Book5.88

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares382,030,000
Market Cap$5.07 billion
Next Earnings DateN/A
OptionableNot Optionable
$13.28
+0.80 (+6.41 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EKTAY News and Ratings via Email

Sign-up to receive the latest news and ratings for EKTAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Elekta AB (publ) (OTCMKTS:EKTAY) Frequently Asked Questions

How has Elekta AB (publ)'s stock price been impacted by Coronavirus (COVID-19)?

Elekta AB (publ)'s stock was trading at $9.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EKTAY shares have increased by 42.9% and is now trading at $13.28.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Elekta AB (publ)?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elekta AB (publ) in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Elekta AB (publ).

What stocks does MarketBeat like better than Elekta AB (publ)?

Wall Street analysts have given Elekta AB (publ) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Elekta AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How often does Elekta AB (publ) pay dividends? What is the dividend yield for Elekta AB (publ)?

Elekta AB (publ) announced a Semi-Annual dividend on Tuesday, July 21st. Investors of record on Friday, August 28th will be paid a dividend of $0.069 per share on Thursday, September 17th. The ex-dividend date is Thursday, August 27th. This is a boost from Elekta AB (publ)'s previous Semi-Annual dividend of $0.05.
View Elekta AB (publ)'s dividend history.

Are investors shorting Elekta AB (publ)?

Elekta AB (publ) saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 300 shares, a decrease of 81.3% from the October 15th total of 1,600 shares. Based on an average daily trading volume, of 13,000 shares, the days-to-cover ratio is presently 0.0 days.
View Elekta AB (publ)'s Short Interest.

Who are some of Elekta AB (publ)'s key competitors?

Some companies that are related to Elekta AB (publ) include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Invitae (NVTA), Natera (NTRA), Veracyte (VCYT), Burning Rock Biotech (BNR), CareDx (CDNA), Genetron (GTH), Personalis (PSNL), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Renalytix AI (RNLX) and DermTech (DMTK).
View all competitors.

Who are Elekta AB (publ)'s key executives?

Elekta AB (publ)'s management team includes the following people:
  • Dr. Laurent Leksell, Founder & Chairman (Age 68)
  • Mr. Gustaf Salford, Acting Pres & CEO (Age 43)
  • Mr. Johan Adeback, Group Treasurer & Acting CFO (Age 56)
  • Cecilia Ketels, Head of Investor Relations
  • Mr. Jonas Bolander, Gen. Counsel, Sec. & Exec. VP (Age 54)
  • Mr. Mattias Thorsson, Head of Corp. Communications & Public Affairs
  • Mr. Ioannis Panagiotelis, Exec. VP of APAC, Japan & South America and Chief Marketing & Sales Officer (Age 48)
  • Ms. Karin Svenske Nyberg, Exec. VP of HR (Age 54)
  • Mr. James P. Hoey, Head of External Relations (Age 62)
  • Mr. John Lapré, Pres of Brachy Solutions (Age 56)

What is Elekta AB (publ)'s stock symbol?

Elekta AB (publ) trades on the OTCMKTS under the ticker symbol "EKTAY."

How do I buy shares of Elekta AB (publ)?

Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Elekta AB (publ)'s stock price today?

One share of EKTAY stock can currently be purchased for approximately $13.28.

How big of a company is Elekta AB (publ)?

Elekta AB (publ) has a market capitalization of $5.07 billion and generates $1.44 billion in revenue each year. Elekta AB (publ) employs 3,800 workers across the globe.

What is Elekta AB (publ)'s official website?

The official website for Elekta AB (publ) is www.elekta.com.

How can I contact Elekta AB (publ)?

Elekta AB (publ)'s mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.